JP2012532106A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532106A5
JP2012532106A5 JP2012517814A JP2012517814A JP2012532106A5 JP 2012532106 A5 JP2012532106 A5 JP 2012532106A5 JP 2012517814 A JP2012517814 A JP 2012517814A JP 2012517814 A JP2012517814 A JP 2012517814A JP 2012532106 A5 JP2012532106 A5 JP 2012532106A5
Authority
JP
Japan
Prior art keywords
methyl
phenyl
trifluoromethyl
trans
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012517814A
Other languages
English (en)
Japanese (ja)
Other versions
JP5689875B2 (ja
JP2012532106A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/040125 external-priority patent/WO2011002696A1/en
Publication of JP2012532106A publication Critical patent/JP2012532106A/ja
Publication of JP2012532106A5 publication Critical patent/JP2012532106A5/ja
Application granted granted Critical
Publication of JP5689875B2 publication Critical patent/JP5689875B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012517814A 2009-06-30 2010-06-28 トランス−4−[[(5s)−5−[[[3,5−ビス(トリフルオロメチル)フェニル]メチル](2−メチル−2h−テトラゾール−5−イル)アミノ]−2,3,4,5−テトラヒドロ−7,9−ジメチル−1h−1−ベンゾアゼピン−1−イル]メチル]−シクロヘキサンカルボン酸 Expired - Fee Related JP5689875B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
US61/221,708 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (3)

Publication Number Publication Date
JP2012532106A JP2012532106A (ja) 2012-12-13
JP2012532106A5 true JP2012532106A5 (enExample) 2013-08-15
JP5689875B2 JP5689875B2 (ja) 2015-03-25

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012517814A Expired - Fee Related JP5689875B2 (ja) 2009-06-30 2010-06-28 トランス−4−[[(5s)−5−[[[3,5−ビス(トリフルオロメチル)フェニル]メチル](2−メチル−2h−テトラゾール−5−イル)アミノ]−2,3,4,5−テトラヒドロ−7,9−ジメチル−1h−1−ベンゾアゼピン−1−イル]メチル]−シクロヘキサンカルボン酸

Country Status (37)

Country Link
US (2) US8299060B2 (enExample)
EP (1) EP2448933B1 (enExample)
JP (1) JP5689875B2 (enExample)
KR (1) KR101404893B1 (enExample)
CN (1) CN102639528B (enExample)
AR (1) AR077208A1 (enExample)
AU (1) AU2010266537B2 (enExample)
BR (1) BRPI1011931A2 (enExample)
CA (1) CA2764425C (enExample)
CL (1) CL2011003263A1 (enExample)
CO (1) CO6480934A2 (enExample)
CR (1) CR20110669A (enExample)
DK (1) DK2448933T3 (enExample)
DO (1) DOP2011000405A (enExample)
EA (1) EA020600B1 (enExample)
EC (1) ECSP11011551A (enExample)
ES (1) ES2435293T3 (enExample)
GT (1) GT201100321A (enExample)
HR (1) HRP20130950T1 (enExample)
IL (1) IL216655A (enExample)
JO (1) JO2867B1 (enExample)
MA (1) MA33385B1 (enExample)
ME (1) ME01606B (enExample)
MX (1) MX2011014024A (enExample)
MY (1) MY157121A (enExample)
NZ (1) NZ596820A (enExample)
PE (1) PE20120538A1 (enExample)
PL (1) PL2448933T3 (enExample)
PT (1) PT2448933E (enExample)
RS (1) RS52988B (enExample)
SG (1) SG177413A1 (enExample)
SI (1) SI2448933T1 (enExample)
TN (1) TN2011000638A1 (enExample)
TW (1) TWI450896B (enExample)
UA (1) UA109409C2 (enExample)
WO (1) WO2011002696A1 (enExample)
ZA (1) ZA201108707B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸
TWI627167B (zh) * 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
RU2627361C2 (ru) 2013-01-31 2017-08-07 Чонг Кун Данг Фармасьютикал Корп. Биарил- или гетероциклические биарилзамещенные производные циклогексена в качестве ингибиторов сетр
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
EP3795695A1 (en) 2014-07-30 2021-03-24 F. Hoffmann-La Roche AG Genetic markers for predicting responsiveness to therapy
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (enExample) 1970-12-15 1974-12-23
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CZ20032898A3 (cs) 2001-04-30 2004-07-14 Pfizer Products Inc. Způsob výroby inhibitorů CETP
SK2332004A3 (en) 2002-08-30 2004-12-01 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
EP1556047A4 (en) 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2004078730A2 (en) 2003-03-04 2004-09-16 Takasago International Corporation Method for producing optically active amines
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
MXPA06003927A (es) 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
ATE433984T1 (de) 2004-03-26 2009-07-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸

Similar Documents

Publication Publication Date Title
JP2012532106A5 (enExample)
JP2014501282A5 (enExample)
HRP20130950T1 (hr) Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina
JP2017504576A5 (enExample)
RU2016123382A (ru) Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения
JP2013538849A5 (enExample)
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
JP2015520140A5 (enExample)
WO2012088607A1 (en) Process for treprostinil salt preparation
JP2008505171A5 (enExample)
CA2948763A1 (en) Process for making benzoxazepin compounds
CA2796933A1 (en) 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives for the therapy of transthyretin amyloidosis
WO2015198227A1 (en) Co-crystal of dapagliflozin with citric acid
JP2015502371A5 (enExample)
JP2007505879A (ja) 既知の抗高脂血症剤の多形体
JP2009040767A5 (enExample)
TWI353970B (enExample)
AU2017303898A1 (en) Production method for pyrazole-amide compound
EP2364307A1 (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
AU2019221837B2 (en) Agents and methods for treating dysproliferative diseases
JP2015512381A5 (enExample)
JP2018521055A (ja) サクビトリルカルシウム塩
HRP20161186T1 (hr) Soli heterociklamidno supstituiranih imidazola sa sulfonskim kiselinama
JP2019524829A5 (enExample)
JP2020503330A5 (enExample)